Table 2. Methodological quality of included studies.
Study | 11-item check list recommended by AHRQ checklist |
||||||||||||
i | ii | iii | iv | v | vi | vii | viii | ix | x | xi | Score | Quality | |
Shin 2021[17] | ★ | ★ | ★ | ★ | ★ | ★ | 6 | M | |||||
Hondur 2021[18] | ★ | ★ | ★ | ★ | 4 | M | |||||||
Fard 2020[19] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 | M | ||||
Robolleda 2019[20] | ★ | ★ | ★ | ★ | ★ | 5 | M | ||||||
Resch 2018[22] | ★ | ★ | ★ | ★ | ★ | 5 | M | ||||||
Fard 2018[24] | ★ | ★ | ★ | ★ | ★ | ★ | 6 | M | |||||
Liu 2017[25] | ★ | ★ | ★ | ★ | 4 | M | |||||||
Lee 2017[26] | ★ | ★ | ★ | ★ | ★ | 5 | M | ||||||
Fard 2016[29] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 | M | ||||
Fard 2016[28] | ★ | ★ | ★ | ★ | ★ | ★ | 6 | M |
AHRQ: Agency for Healthcare Research and Quality; H: High quality; M: Moderate quality; L: Low quality; high quality (score: 8-11); moderate quality (score: 4-7); low quality (score: 0-3). i: Define the source of information; ii: List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; iii: Indicate time period used for identifying patients; iv: Indicate whether or not subjects were consecutive if not population-based; v: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; vi: Describe any assessments undertaken for quality assurance purposes; vii: Explain any patient exclusions from analysis; viii: Describe how confounding was assessed and/or controlled; ix: If applicable, explain how missing data were handled in the analysis; x: Summarize patient response rates and completeness of data collection; xi: Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.